Free Trial

Assembly Biosciences (ASMB) Competitors

Assembly Biosciences logo
$29.45 +0.37 (+1.27%)
Closing price 04:00 PM Eastern
Extended Trading
$29.64 +0.19 (+0.63%)
As of 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ASMB vs. OMER, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRX

Should you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Omeros (OMER), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry.

Assembly Biosciences vs. Its Competitors

Assembly Biosciences (NASDAQ:ASMB) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -117.20%. Omeros' return on equity of 0.00% beat Assembly Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Assembly Biosciences-117.20% -149.01% -39.04%
Omeros N/A N/A -55.49%

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 5.3% of Assembly Biosciences shares are owned by company insiders. Comparatively, 12.9% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Omeros had 23 more articles in the media than Assembly Biosciences. MarketBeat recorded 33 mentions for Omeros and 10 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.53 beat Assembly Biosciences' score of 0.21 indicating that Omeros is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Assembly Biosciences
0 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Omeros
8 Very Positive mention(s)
8 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Assembly Biosciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500.

Assembly Biosciences has higher revenue and earnings than Omeros. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Assembly Biosciences$28.52M7.92-$40.18M-$5.58-5.28
OmerosN/AN/A-$156.82M-$2.11-3.84

Assembly Biosciences presently has a consensus target price of $41.25, indicating a potential upside of 40.07%. Omeros has a consensus target price of $27.50, indicating a potential upside of 239.51%. Given Omeros' stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Assembly Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Assembly Biosciences
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Omeros
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
2.75

Summary

Omeros beats Assembly Biosciences on 12 of the 16 factors compared between the two stocks.

Get Assembly Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASMB vs. The Competition

MetricAssembly BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$223.11M$4.47B$6.11B$10.51B
Dividend YieldN/A0.89%5.73%4.81%
P/E Ratio-5.2810.8584.5227.09
Price / Sales7.9221.85609.45131.82
Price / CashN/A7.0637.1661.22
Price / Book5.614.2712.246.52
Net Income-$40.18M-$134.23M$3.32B$276.75M
7 Day Performance11.09%1.74%0.76%0.92%
1 Month Performance42.82%18.13%8.03%4.20%
1 Year Performance62.71%66.79%71.13%37.86%

Assembly Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASMB
Assembly Biosciences
3.5093 of 5 stars
$29.45
+1.3%
$41.25
+40.1%
+65.3%$223.11M$28.52M-5.28100Analyst Forecast
OMER
Omeros
4.3192 of 5 stars
$4.61
+0.7%
$18.00
+290.5%
+137.4%$311.70MN/A-2.18210Trending News
Analyst Forecast
Analyst Revision
Gap Down
CPIX
Cumberland Pharmaceuticals
0.6329 of 5 stars
$3.09
-1.3%
N/A+173.8%$46.83M$37.87M-14.0580
LLY
Eli Lilly and Company
4.9817 of 5 stars
$845.40
+0.7%
$938.94
+11.1%
-10.7%$794.90B$45.04B55.2547,000Trending News
Analyst Upgrade
Gap Down
JNJ
Johnson & Johnson
4.844 of 5 stars
$188.23
-0.2%
$189.12
+0.5%
+16.7%$454.31B$88.82B20.13138,100Trending News
Earnings Report
Dividend Announcement
Analyst Forecast
Analyst Revision
ABBV
AbbVie
4.6885 of 5 stars
$230.28
-1.6%
$229.14
-0.5%
+19.1%$413.22B$56.33B109.6655,000Trending News
Analyst Downgrade
Options Volume
Analyst Revision
MRK
Merck & Co., Inc.
5 of 5 stars
$88.83
-0.4%
$104.31
+17.4%
-24.2%$222.78B$63.62B13.6975,000Trending News
Analyst Revision
PFE
Pfizer
4.9564 of 5 stars
$26.45
-3.4%
$28.41
+7.4%
-18.3%$155.61B$63.63B14.0781,000Trending News
BMY
Bristol Myers Squibb
4.974 of 5 stars
$45.16
-0.6%
$57.14
+26.5%
-18.7%$92.51B$48.30B18.2134,100Trending News
Analyst Forecast
Analyst Revision
ZTS
Zoetis
4.8798 of 5 stars
$145.39
-0.7%
$200.88
+38.2%
-26.4%$64.89B$9.26B25.0213,800Analyst Revision
RPRX
Royalty Pharma
4.9874 of 5 stars
$36.13
+0.2%
$46.00
+27.3%
+28.8%$21.04B$2.31B20.8880Positive News
Dividend Announcement
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:ASMB) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners